OFIX Form 4 Details Equity Award to Director Alan Lee Bazaar
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Orthofix Medical (NASDAQ:OFIX) submitted a routine Form 4 disclosing that director Alan Lee Bazaar received 18,841 deferred stock units on 06/18/2025 as part of standard board compensation.
The units vest in full on the first anniversary of the grant date, contingent upon continued service, and convert into common stock within 45 days of the director’s termination of service. The transaction price is recorded as $0, indicating a non-cash equity award. After the grant, Bazaar beneficially owns 49,824 shares, which include 24,088 previously reported deferred stock units. No shares were sold or disposed of, and the filing notes no other material changes.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bazaar Alan Lee
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 18,841 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 49,824 shares (Direct)
Footnotes (1)
- Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Includes 24,088 previously reported deferred stock units.
FAQ
What insider transaction did Orthofix Medical (OFIX) report on June 29, 2025?
The Form 4 shows director Alan Lee Bazaar was granted 18,841 deferred stock units on 06/18/2025 at a stated price of $0.
When do the newly granted deferred stock units to OFIX’s director vest?
According to the filing, all 18,841 units vest on the first anniversary of the 06/18/2025 grant date, provided the director remains in service.